Aclaris Therapeutics

Aclaris Therapeutics

Aclaris Therapeutics is a publicly traded biopharmaceutical company headquartered in Wayne, Pennsylvania, with additional operations in St. Louis, Missouri. The company has not publicly disclosed a founding year, nor does it name specific principals on its website. The company's strategy centers on developing therapies for immuno-inflammatory conditions, particularly in dermatology, where it aims to address underserved patient populations. Aclaris operates with a focus on scientific innovation, exploring what it terms 'white spaces'—areas where significant treatment gaps remain. Its pipeline and research efforts are directed at translating discoveries into everyday clinical victories, but no specific portfolio companies, deals, or co-investors are named in available sources. Geographic footprint is limited to its headquarters in Wayne, Pennsylvania, and an office in St. Louis, Missouri (per the firm's website). Aclaris does not disclose team size, AUM, deployment figures, or any adjacent vehicles such as philanthropic foundations or real-asset arms. No recent dated operational events from the last 24 months are publicly available from the firm's own communications. The company's LinkedIn profile was not captured, limiting additional professional context. The firm's structural differentiator is its niche focus on scientific innovation in immuno-inflammatory conditions, particularly dermatology, where it positions itself to fill gaps left by larger pharmaceutical players. Its public status and transparent communication of pipeline priorities through its website make it distinct from privately held single-family offices, operating more as a conventional biotech firm than as an asset manager.